ストックスクリーナーアプリを入手
6.32
2.00%
-0.18
前日終値:
$6.50
開ける：
$6.5
24時間の取引高:
214.69K
Relative Volume:
0.24
時価総額：
$513.45M
収益：
$380.79M
当期純損益:
$49.27M
株価収益率:
9.0286
EPS:
0.7
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
+26.14%
1か月 パフォーマンス:
+34.96%
6か月 パフォーマンス:
+64.60%
1年 パフォーマンス:
+230.05%
1日の値動き範囲:
$6.15
$6.59
1週間の範囲:
$4.80
$6.70
52週間の値動き範囲:
$1.62
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-683-0917
住所
43 THORNDIKE STREET, CAMBRIDGE
AMLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
6.34 | 513.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.98 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
530.50 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.75 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at Citigroup - Defense World
Citi initiates Amylyx stock with buy rating on promising pipeline By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Citi initiates Amylyx stock with buy rating on promising pipeline - Investing.com
Amylyx Pharmaceuticals (AMLX): Citigroup Initiates Coverage with 'Buy' Rating | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at Citi - TipRanks
Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage | AMLX Stock News - GuruFocus
Diabetes Insipidus Market Statistics Expected to Experience - openPR.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
# H.C. Wainwright reiterates Buy rating on AMYLYX stock ahead of trial - Investing.com India
Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
AMX0114 receives FDA fast track status for the treatment of ALS - ALS News Today
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wellington Management Group LLP Purchases New Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Ameriprise Financial Inc. Purchases Shares of 50,428 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting - TipRanks
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation - marketscreener.com
Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AM - GuruFocus
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World
TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus
TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at TD Cowen - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com
Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
Amylyx Pharmaceuticals Inc (AMLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Mar 31 '25 |
Sale |
3.47 |
12,425 |
43,082 |
194,375 |
| Mazzariello Gina | Chief Legal Officer |
Mar 31 '25 |
Sale |
3.48 |
9,192 |
31,954 |
187,969 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.47 |
21,490 |
74,482 |
3,355,280 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.46 |
21,490 |
74,454 |
3,355,276 |
| Zeiher Bernhardt G | Director |
Mar 20 '25 |
Buy |
3.70 |
10,000 |
37,005 |
10,000 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.15 |
4,595 |
14,483 |
3,196,648 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.17 |
4,595 |
14,549 |
3,196,652 |
| Mazzariello Gina | Chief Legal Officer |
Mar 03 '25 |
Sale |
3.12 |
1,611 |
5,022 |
133,310 |
| Mazzariello Gina | Chief Legal Officer |
Feb 24 '25 |
Sale |
3.15 |
4,169 |
13,145 |
134,921 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):